Compare Citius Pharmaceuticals Inc (CTXR) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Zillow Group Inc Class A — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: Zillow Group Inc Class A is far larger — about 483.8× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 1,361,381). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Zillow Group Inc Class A for 86 Days on average.
| CTXR | ZG | |
|---|---|---|
Market Cap | $13.62M | $6.59B |
Volume | 132,438 | 1,361,381 |
Sector | Health | Media |
52-Week High | $1.82 | $74.58 |
52-Week Low | $0.48 | $27.70 |
Typical Hold Time | 17 Days | 86 Days |
Enterprise Value | $3.79M | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Zillow Group (ZG) trades at $29.53, up 5.58% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported a return to profitability in 2025 with net income of $23 million, and revenue is projected to grow to $2.8 billion in 2026. Recent news highlights the company's focus on AI integration and a challenging housing market environment.
The outlook is cautiously optimistic, with a consensus price target of $48.87 suggesting significant upside. Key opportunities include revenue growth and market share gains, while risks involve housing market volatility and intense competition. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
